- Home
- KURA
KURA
Kura Oncology Inc.
as of 12-18-2025 3:40pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.0B | IPO Year: | N/A |
| Target Price: | $25.00 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.41 - $12.49 | Next Earning Date: | 11-04-2025 |
| Revenue: | $104,029,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 138.16% | Revenue Growth (next year): | 67.37% |
AI-Powered KURA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Kura Oncology Inc. (KURA)
Director
Avg Cost/Share
$10.98
Shares
10,000
Total Value
$109,764.00
Owned After
23,983
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$8.94
Shares
8,805
Total Value
$78,736.07
Owned After
148,043
SEC Form 4
President and CEO
Avg Cost/Share
$8.94
Shares
36,615
Total Value
$327,418.65
Owned After
246,853
SEC Form 4
SVP, Finance & Accounting
Avg Cost/Share
$8.94
Shares
4,541
Total Value
$40,606.53
Owned After
109,829
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$8.94
Shares
6,892
Total Value
$61,629.64
Owned After
63,375
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$8.94
Shares
8,891
Total Value
$79,505.10
Owned After
99,676
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$8.94
Shares
12,314
Total Value
$110,114.25
Owned After
158,439
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hasnain Faheem | KURA | Director | Dec 9, 2025 | Sell | $10.98 | 10,000 | $109,764.00 | 23,983 | |
| Bair Teresa Brophy | KURA | Chief Legal Officer | Sep 29, 2025 | Sell | $8.94 | 8,805 | $78,736.07 | 148,043 | |
| WILSON TROY EDWARD | KURA | President and CEO | Sep 29, 2025 | Sell | $8.94 | 36,615 | $327,418.65 | 246,853 | |
| DOYLE THOMAS JAMES | KURA | SVP, Finance & Accounting | Sep 29, 2025 | Sell | $8.94 | 4,541 | $40,606.53 | 109,829 | |
| FORD KATHLEEN | KURA | Chief Operating Officer | Sep 29, 2025 | Sell | $8.94 | 6,892 | $61,629.64 | 63,375 | |
| Powl Brian T. | KURA | Chief Commercial Officer | Sep 29, 2025 | Sell | $8.94 | 8,891 | $79,505.10 | 99,676 | |
| Leoni Mollie | KURA | Chief Medical Officer | Sep 29, 2025 | Sell | $8.94 | 12,314 | $110,114.25 | 158,439 |
Compare KURA vs Leading Stocks
See how KURA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.